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RESEARCH NOTE
Prevalence and significance 
of Mycoplasma genitalium in women living 
with HIV in Denmark
Anne Marie Rosendahl Madsen1,5* , Kristina Thorsteinsson2, Anne‑Mette Lebech2, Merete Storgaard3, 
Terese L. Katzenstein4, Frederikke F. Rönsholt4, Isik Somuncu Johansen5, Gitte Pedersen6, 
Lars Noerregaard Nielsen7, Aase Bengaard Andersen4,5 and Jørgen Skov Jensen8
Abstract 
Objective: Mycoplasma genitalium (M. genitalium) is a sexually transmitted pathogen associated with urethritis, cer‑
vicitis, and pelvic inflammatory disease. Previous studies have shown a strong association between M. genitalium and 
HIV infection, therefore screening and treatment for M. genitalium has been suggested as part of HIV prevention strat‑
egies. The objective of this study was to determine the prevalence of M. genitalium in women living with HIV (WLWH) 
in Denmark, and to compare the result with data on symptoms from the lower abdomen, sexual habits and immune 
status. 234 women, recruited from Danish HIV centres as part of a larger observational study on aspects of living with 
HIV as a woman (the SHADE study), were included.
Results: We tested cervical samples for M. genitalium by specific PCR. We found three samples positive (1.3%). The 
women were between 30 and 50 years old, all were of Asian origin, sexually active, and on antiretroviral treatment 
with supressed HIV RNA and CD4 count >350 cells/µL. None reported symptoms from the lower abdomen. The preva‑
lence of M. genitalium infection in WLWH in Denmark is low, thus systematic screening for M. genitalium in this group 
does not seem relevant.
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Introduction
Mycoplasma genitalium (M. genitalium) is a well-known 
sexually transmitted pathogen. It is an important cause 
of non-gonococcal urethritis in men, and in women it 
has been associated with cervicitis, urethritis and pelvic 
inflammatory disease [1]. Data from the last decade show 
a strong association between M. genitalium and HIV 
[2–4]. Women living with HIV (WLWH) infected with 
M. genitalium have been found to shed higher amounts 
of HIV in vaginal fluids, thereby possibly enhancing HIV 
transmission [5]. Infection with M. genitalium can lead to 
cervical inflammation, and it is possible that the infection 
also increases the risk of acquiring HIV infection, as is 
the case in other sexually transmitted diseases (STD) [6].
The prevalence of M. genitalium in women in the gen-
eral population of high-income countries ranges from 1 
to 4%, but is 10% or even higher among women attending 
STD clinics [7–9]. In the US, a survey of WLWH showed 
a 9.9% prevalence of M. genitalium infection [10]. Stud-
ies from Africa have documented a much higher preva-
lence in risk groups [11]. They also documented higher 
prevalence of M. genitalium infection among HIV posi-
tive women compared with HIV negative women, and 
it seems the infection persists longer in the HIV posi-
tive [12, 13]. One longitudinal study showed a twofold 
increased risk of being infected with HIV when M. geni-
talium positive [14].
Established risk factors for acquiring M. genitalium 
infection are young age, multiple sexual partners, 
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smoking, black ethnicity, and possibly bacterial vaginosis 
[9, 15].
There are no data on M. genitalium infection in WLWH 
in Denmark or other parts of Scandinavia. We obtained 
cervical samples from WLWH participating in a larger 
observational study on aspects of living with HIV as a 
woman (the SHADE study). The aim of this study was to 
determine the prevalence of M. genitalium in WLWH in 
Denmark, and secondly to compare the result with data 
on symptoms from the lower abdomen, sexual habits and 
immune status.
Main text
Registries
The Civil Registration System (CRS) The CRS is a national 
registry of all Danish residents [16]. A 10-digit personal 
identification number (PIN) is assigned to everyone at 
birth or immigration. The PIN was used as a linkage to 
the Danish HIV Cohort Study (DHCS).
Danish HIV Cohort Study (DHCS) The DHCS is a pro-
spective, observational, nationwide cohort study of all 
people living with HIV seen at the Danish HIV clinics 
since January 1995 [17]. From the DHCS we obtained 
data on baseline HIV characteristics.
Methods
Study design
We tested cervical samples collected from 234 WLWH. 
Women were recruited from six Danish HIV centres 
as part of the SHADE cohort; study on HIV, cervical 
abnormalities and infections in women in Denmark. 
The SHADE cohort is a multicenter, prospective, obser-
vational cohort study of WLWH in Denmark attending 
regular outpatient care for their HIV infection. The study 
focuses on STD, contraception, sexual activity, human 
papillomavirus (HPV) infection, cervical cytological 
abnormalities, and other aspects of living with HIV as a 
woman. Results from the SHADE study have been pub-
lished elsewhere [18].
Women were asked to participate if they had a known 
HIV-1 infection and were ≥18  years of age. Exclusion 
criteria were pregnancy and alcohol and/or drug abuse 
impeding adherence to the protocol. Of 1392 eligible 
women in the DHCS, 334 were included in the SHADE 
cohort. Women were enrolled between February 2011 
and February 2012. The 234 WLWH included in the pre-
sent study were those attending the 2 years follow-up of 
the SHADE study from February 2013–February 2014. At 
enrolment, women were tested for Chlamydia trachoma-
tis, Neisseria gonorrhoeae, syphilis, and herpes sim-
plex (HSV-1 and HSV-2). Gynaecological examinations 
were performed at entry and at 6, 12 and 24  months’ 
follow-up. An interview survey was performed to obtain 
background information. The questionnaire used has 
been described in detail elsewhere [18].
At entry, written and oral informed consent was 
obtained from all participants. The protocol has been 
approved by the Danish Data Protection Agency and 
by the Danish National Committee on Health Research 
Ethics.
Study population
The median age at inclusion in the study was 44  years 
(range 25–78  years). Treatment status was generally 
good, with 94% of the women on antiretroviral treat-
ment (ART), and 86% on ART with an undetectable 
HIV RNA. CD4 count was 350 cells/µL or above in 80% 
of the cases. Symptoms from the lower abdomen were 
reported in 21% of the cases, most frequently vaginal 
discharge and abnormal menstrual bleeding. When 
asked about the number of lifetime sexual partners, 
67% of the women reported less than 15 partners, 33% 
reported more than 15 partners, and of those, 18% had 
more than 25 lifetime sexual partners. When asked 
about sexual activity in the previous 6 months up to the 
follow up visit, 71% were sexually active. Furthermore, 
56% were married or cohabitating and 32% reported 
to be single. Baseline characteristics of the WLWH are 
listed in Table 1.
Analyses
Samples were obtained by the treating physician per-
forming a gynecological examination. Flocked swabs 
were collected in UTM transport medium, and M. geni-
talium was detected by TaqMan™ PCR amplifying a con-
served region of the MgPa adhesin gene [19]. Positive 
results were confirmed by conventional PCR amplifying 
the 23S rRNA gene, and the resulting PCR products were 
subsequently sequenced to detect macrolide resistance 
mediating mutations [20]. The women who tested posi-
tive for M. genitalium were offered treatment with oral 
azithromycin for 5  days (500  mg  day one, followed by 
250 mg daily day 2–5). Per protocol treatment in case of 
macrolide resistance was oral moxifloxacin 400 mg daily 
for 7 days (Additional file 1).
Statistical analyses
Continuous variables were summarized as median and 
interquartile ranges (IQR) and compared using Wilcoxon 
rank sum test. Categorical variables were reported as 
counts and percentages and compared with Chi square 
test or Fisher’s exact test as appropriate. Further details 
on the statistical analyses on the SHADE cohort have 
been published previously [18].
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Results
Of the 234 women, three (1.3%) were PCR positive for 
M. genitalium. All carried a macrolide susceptible strain. 
The prevalence was too low to perform adjusted analyses 
aiming at predicting associated factors.
Of the WLWH in this study, 45% were white, 40% were 
black and 14% were Asian. Interestingly, all three M. 
genitalium positive women were from Asia (Thailand); 
thus, the prevalence among women from Asia was 10% 
(95% CI 2.0–27.0%) which was significantly higher than 
the 0% prevalence found in both white and black women 
(p = 0.01 and p = 0.02, respectively). Characteristics of 
the M. genitalium positive women are shown in Table 2.
Discussion
We found a relatively low prevalence of 1.3% of M. geni-
talium infections in this population. The result is com-
parable to the prevalence of 1–4% reported in general 
populations in high-income countries [7–9], but much 
lower than in studies of African and American WLWH, 
where the prevalence generally has been much higher 
[11, 21]. Interestingly, all M. genitalium infected women 
were from Thailand. Although numbers were small, all 
three were infected with macrolide susceptible strains 
of M. genitalium, which may be surprising as the level 
of macrolide resistance in Thailand is expected to be 
high, although no precise figures exist. If the women 
were infected in Denmark, we would expect nearly half 
to carry resistance mediating mutations [20]. The low 
prevalence of M. genitalium could be explained by sev-
eral factors. The median age is relatively high in the pre-
sent study compared to other studies of both WLWH 
and general populations. Furthermore, the women in this 
population seemed to be less sexually active than WLWH 
in other study populations. The majority of the women 
were in a relationship or had a regular partner. A recent 
study from France showed a similar low prevalence of M. 
genitalium (3.8%) among WLWH [22]. The study popu-
lation was comparable to the present study population 
with respect to the median age (41.3 and 44 years respec-
tively), race (42 and 55% non-white respectively), and 
Table 1 Baseline characteristics of  study participants 
(n = 234)
Duration of HIV infection (years), median (IQR) 12.7 (7.5–17.8)
Age at inclusion (years), median (IQR) 44.4 (38.8–50.8)
Race, n (%)
 White 105 (45.1)
 Asian 32 (13.7)
 Black 94 (40.3)
 Other 2 (0.9)
 Missing 1
Place of HIV transmission, n (%)
 Denmark 84 (39.6)
 Europe + US 16 (7.6)
 Africa 86 (40.6)
 Asia 26 (12.3)
 Other 0 (0)
 Missing 22
Mode of HIV transmission, n (%)
 Heterosexual 210 (92.5)
 IDU 12 (5.3)
 Other 5 (2.2)
 Missing 7
CD4 count at inclusion (cells/μL), n (%)
 <200 11 (5.0)
 200–350 33 (14.9)
 >350 177 (80.1)
 Missing 13
ART at inclusion, n (%)
 Yes 220 (94.0)
 No 14 (6.0)
On ART with undetectable HIV  RNAa, n (%)
 Yes 182 (85.5)
 No 31 (14.6)
 Missing 9
Lifetime sexual partners at inclusion, n (%)
 <4 58 (24.8)
 5–9 57 (24.4)
 10–14 40 (17.1)
 15–25 36 (15.4)
 26–40 13 (5.5)
 >40 29 (12.4)
 Does not wish to respond 1 (0.4)
Sexual activity in the past 6 months, n (%)
 Yes 165 (70.8)
 No 68 (29.2)
 Missing 1
Symptoms from the lower abdomen, n (%)
 Yes 50 (21.4)
 No 184 (78.6)
Marital status
 Married 77 (41.2)
 Cohabitating 27 (14.4)
ART antiretroviral treatment, IDU intravenous drug use
a Undetectable = HIV RNA <40 copies/mL
Table 1 continued
 Regular partner (not cohabitating) 23 (12.3)
 Single 60 (32.1)
 Missing 47
Smoking status at inclusion, n (%)
 Current smoker/ex‑smoker 98 (41.9)
 Never smoker 136 (58.1)
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sexual activity. Many of the studies carried out in Africa 
included women in high-risk populations.
Conclusions
The prevalence of M. genitalium was relatively low in 
this study population. The result is comparable to the 
prevalence reported in the general populations in high-
income countries. Screening for M. genitalium as part of 
HIV prevention strategies does not seem relevant in this 
setting.
Limitations
With only three positive results, there was no basis for a 
statistical analysis of risk factors associated with M. geni-
talium infection. The women who participated in this 
study were generally older and less sexually active than 
the women in most other studies of HIV and M. geni-
talium, and most of them were successfully treated with 
fully supressed HIV RNA.
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Table 2 Mycoplasma genitalium positive women
IDU intravenous drug-use, ART antiretroviral treatment, STD sexually transmitted diseases
a Age is indicated as a 10-year range
b At inclusion
Mycoplasma genitalium positive women #1 #2 #3
Age group at inclusion (years)a 30–40 40–50 30–40
Race Asian Asian Asian
Origin Thailand Thailand Thailand
Place of HIV transmission Asia Asia Asia
Mode of HIV transmission IDU Heterosexual Heterosexual
CD4 (cells/µL) >350 >350 >350
HIV RNA load Undetectable Undetectable Undetectable
Smoking Smoker Non‑smoker Smoker
On ART Yes Yes Yes
Sexually active Yes Yes Yes
Positive for other  STDb No No No
Lifetime sexual partners >40 <4 >40
Marital status Unknown Married Single
Symptoms from the lower abdomen None None None
Page 5 of 5Madsen et al. BMC Res Notes  (2017) 10:468 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Consent for publication
Not applicable.
Ethics approval and consent to participate
The protocol has been approved by the Danish Data Protection Agency 
(2015‑231‑0126, 2012‑58‑0004 and 2012‑41‑0005) and by the Danish National 
Committee on Health Research Ethics (Approval Numbers: H‑3‑2010‑119 and 
H‑2‑2014‑102). At entry, written and oral informed consent was obtained from 
all participants.
Funding
This study has received funding from the Danish Female Doctors Association, 
The Agnethe Løvgreen Grant.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
Received: 7 March 2017   Accepted: 31 August 2017
References
 1. Taylor‑Robinson D, Jensen JS. Mycoplasma genitalium: from Chrysalis to 
multicolored butterfly. Clin Microbiol Rev. 2011;24:498–514.
 2. Mavedzenge SN, Weiss HA. Association of Mycoplasma genitalium 
and HIV infection: a systematic review and meta‑analysis. Aids. 
2009;23:611–20.
 3. Mavedzenge SN, Muller EE, Lewis DA, Chipato T, Morrison CS, Weiss HA. 
Mycoplasma genitalium is associated with increased genital HIV type 1 
RNA in Zimbabwean women. J Infect Dis. 2015;211:1388–98.
 4. Vandepitte J, Weiss HA, Bukenya J, Kyakuwa N, Muller E, Buve A, Van 
der Stuyft P, Hayes RJ, Grosskurth H. Association between Mycoplasma 
genitalium infection and HIV acquisition among female sex workers in 
Uganda: evidence from a nested case–control study. Sex Transm Infect. 
2014;90:545–9.
 5. Manhart LE, Mostad SB, Baeten JM, Astete SG, Mandaliya K, Totten PA. 
High Mycoplasma genitalium organism burden is associated with shed‑
ding of HIV‑1 DNA from the cervix. J Infect Dis. 2008;197:733–6.
 6. Fleming DT, Wasserheit JN. From epidemiological synergy to public 
health policy and practice: the contribution of other sexually transmit‑
ted diseases to sexual transmission of HIV infection. Sex Transm Infect. 
1999;75:3–17.
 7. Andersen B, Sokolowski I, Ostergaard L, Kjolseth Moller J, Olesen F, Jensen 
JS. Mycoplasma genitalium: prevalence and behavioural risk factors in the 
general population. Sex Transm Infect. 2007;83:237–41.
 8. Weinstein SA, Stiles BG. A review of the epidemiology, diagnosis and 
evidence‑based management of Mycoplasma genitalium. Sex Health. 
2011;8:143–58.
 9. Cazanave C, Manhart LE, Bebear C. Mycoplasma genitalium, an emerging 
sexually transmitted pathogen. Med Mal Infect. 2012;42:381–92.
 10. Gatski M, Martin DH, Theall K, Amedee A, Clark RA, Dumestre J, Chhabra 
P, Schmidt N, Kissinger P. Mycoplasma genitalium infection among HIV‑
positive women: prevalence, risk factors and association with vaginal 
shedding. Int J STD AIDS. 2011;22:155–9.
 11. Vandepitte J, Muller E, Bukenya J, Nakubulwa S, Kyakuwa N, Buve A, Weiss 
H, Hayes R, Grosskurth H. Prevalence and correlates of Mycoplasma geni-
talium infection among female sex workers in Kampala, Uganda. J Infect 
Dis. 2012;205:289–96.
 12. Vandepitte J, Weiss HA, Kyakuwa N, Nakubulwa S, Muller E, Buve A, Van 
der Stuyft P, Hayes R, Grosskurth H. Natural history of Mycoplasma geni-
talium infection in a cohort of female sex workers in Kampala, Uganda. 
Sex Transm Dis. 2013;40:422–7.
 13. Cohen CR, Nosek M, Meier A, Astete SG, Iverson‑Cabral S, Mugo NR, Tot‑
ten PA. Mycoplasma genitalium infection and persistence in a cohort of 
female sex workers in Nairobi, Kenya. Sex Transm Dis. 2007;34:274–9.
 14. Mavedzenge SN, Van Der Pol B, Weiss HA, Kwok C, Mambo F, Chipato 
T, Van der Straten A, Salata R, Morrison C. The association between 
Mycoplasma genitalium and HIV‑1 acquisition in African women. Aids. 
2012;26:617–24.
 15. Oakeshott P, Aghaizu A, Hay P, Reid F, Kerry S, Atherton H, Simms I, Taylor‑
Robinson D, Dohn B, Jensen JS. Is Mycoplasma genitalium in women the 
“New Chlamydia?” A community‑based prospective cohort study. Clin 
Infect Dis. 2010;51:1160–6.
 16. Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 
2011;39:22–5.
 17. Obel N, Engsig FN, Rasmussen LD, Larsen MV, Omland LH, Sorensen 
HT. Cohort profile: the Danish HIV cohort study. Int J Epidemiol. 
2009;38:1202–6.
 18. Thorsteinsson K, Ladelund S, Storgaard M, Ronsholt FF, Johansen IS, 
Pedersen G, Nielsen LN, Bonde J, Westh H, Obel N, et al. Sexually transmit‑
ted infections and use of contraceptives in women living with HIV in 
Denmark—the SHADE cohort. BMC Infect Dis. 2016;16:81.
 19. Jensen JS, Bjornelius E, Dohn B, Lidbrink P. Use of TaqMan 5′ nuclease 
real‑time PCR for quantitative detection of Mycoplasma genitalium DNA 
in males with and without urethritis who were attendees at a sexually 
transmitted disease clinic. J Clin Microbiol. 2004;42:683–92.
 20. Salado‑Rasmussen K, Jensen JS. Mycoplasma genitalium testing pattern 
and macrolide resistance: a Danish nationwide retrospective survey. Clin 
Infect Dis. 2014;59:24–30.
 21. Gomih‑Alakija A, Ting J, Mugo N, Kwatampora J, Getman D, Chitwa M, 
Patel S, Gokhale M, Kimani J, Behets FS, Smith JS. Clinical characteristics 
associated with Mycoplasma genitalium among female sex workers in 
Nairobi, Kenya. J Clin Microbiol. 2014;52:3660–6.
 22. Cazanave C, Lawson‑Ayayi S, Hessamfar M, Neau D, Dupon M, Morlat 
P, Dabis F, de Barbeyrac B, Bebear C, Pereyre S. Prevalence of Myco-
plasma genitalium among HIV‑infected women, Agence Nationale de 
Recherches sur le SIDA et les hepatites virales CO3 Aquitaine Cohort, 
France. Sex Transm Dis. 2013;40:653–4.
